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The growing use of molecular imaging helps to control
and monitor dosage for increased safety and eﬀectiveness.
Molecular imaging agents become the scientiﬁc tools for
moving a concept from bench work to clinic product de-
velopment. This special issue provides original research
and review of new trends in molecular imaging agent
development.
Among clinic molecular imaging modalities, radionu-
clide imaging technique is the most sensitive and could pro-
vide target-speciﬁc information. The radiotracer could non-
invasively assess disease treatment endpoints which used
to rely almost exclusively on biopsies and histopathological
assays.
L.-H. Shen et al. (Taiwan) reviewed molecular imaging
in the diagnosis and management of CNS disorders. F.-L.
Kong et al. (USA), N. Tsao et al. (USA), and C.-L. Ho et al.
(Taiwan) report pharmacokinetics and dosimetry of molec-
ular imaging compounds in oncology. M.-H. Liao et al.
(Taiwan), X. Wang et al. (China), C. Wu et al. (China)
and M. Tian et al. (USA) reported that molecular imaging
techniques play a major role in the development of novel
therapies since they measure target expressions (apoptosis,
glycolysis) as well as function, pathway activities, and cell
migration in the intact organism. Y.-F. Wang et al. and
M.-Y. Chao et al. (Taiwan) described the kit probe for
99mTc-labeling which is crucial for centralized drug process.
The kit probe may allow theranostic concept. A theranostic
agent would be more accurate in the evaluation of patient
response to treatment. The radiotracer could also be used
for radionuclide therapy as reported by C. Wang et al.
(China). Hybrid molecular imaging modalities (PET/CT,
SPECT/CT) provide high-sensitivity functional and high-
resolution anatomical imaging which are important in
design-personalized treatment. M.-C. Chen et al. (Taiwan)
reported the value of using I-131 NP-59 SPECT/CT to
diagnose patients with subclinical or atypical features of
primary aldosteronism. To proof of concept for molecular
biology ﬁndings using diﬀerent imaging modalities (optical,
sonography) were described by Z. Pu et al. (China).
In summary, molecular imaging enables the comprehen-
sive characterization of therapeutic intervention and can be
used in preclinical studies, pharmacokinetic studies, dose-
ﬁnding studies, and proof-of-concept studies. Molecular
imaging technologies promote the discovery and develop-
ment of personalized medicine.
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